Diagnosis and treatment of thrombocythemia in myeloproliferative disorders

ONCOLOGY

Volumn 15, Issue 8, 2001, Pages 989-998

  Gilbert, Harriet S ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANAGRELIDE; BIOLOGICAL RESPONSE MODIFIER; ENZYME INHIBITOR; HYDROXYUREA; QUINAZOLINE DERIVATIVE;

HUMAN; POLYCYTHEMIA VERA; REVIEW; THROMBOCYTOSIS;

BIOLOGICAL RESPONSE MODIFIERS; ENZYME INHIBITORS; HUMANS; HYDROXYUREA; INTERFERON-ALPHA; POLYCYTHEMIA VERA; QUINAZOLINES; THROMBOCYTOSIS;

EID: 0035433547     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (3)

1. Gilbert HS: The role of anagrelide, hydroxyurea, and interferon-α in treating thrombocythemia of myeloproliferative disease: A new approach for the Millennium. International Society of Hematology program book, pp 141-143, 1999.
2. Gilbert HS: Diagnosis and treatment of polycythemia vera, agnogenic myeloid metaplasia, and essential thrombocythemia, in Wiernik PH, Canellos GP, Kyle RA, et al (eds): Neoplastic Diseases of the Blood, p 123. New York, Churchill Livingstone, 1991.
3. Sterkers Y, Preudhomme C, Lai JL, et al: Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea. Blood 91(2):616-622, 1998.